JP Morgan Chase’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

JP Morgan Chase’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-31,600	Closed	-$2.21M	–	7156
2022 Q3	$2.21M	Buy	+31,600	New	+$2.34M	﹤0.01%	3388
2021 Q4	–	Sell	-6,400	Closed	-$1.13M	–	7067
2021 Q3	$1.13M	Buy	+6,400	New	+$1.03M	﹤0.01%	4217
2020 Q4	–	Sell	-8,200	Closed	-$1.36M	–	6026
2020 Q3	$1.36M	Buy	+8,200	New	+$1.12M	﹤0.01%	3471
2019 Q2	–	Sell	-146,300	Closed	-$10.7M	–	6080
2019 Q1	$10.7M	Buy	+146,300	New	+$9.95M	﹤0.01%	1990
2018 Q3	–	Sell	-27,000	Closed	-$1.33M	–	5884
2018 Q2	$1.33M	Buy	+27,000	New	+$1.02M	﹤0.01%	3666

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's MRTX Position: Q1 2024 in Review

JP Morgan Chase sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 108,407 shares — an estimated $6.37M sold.

JP Morgan Chase first reported a position in MRTX in Q3 2014 and held it in 35 quarters. The position peaked at $78.9M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

JP Morgan Chase reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
JP Morgan Chase sold 108,407 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $6.37M.
JP Morgan Chase first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2014 and held it in 35 quarters.
JP Morgan Chase's Mirati Therapeutics, Inc. Common Stock position peaked at $78.9M in Q4 2020.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.